7 Williams ES, Owens DS, Drezner JA, et al. Electrocardiogram interpretation in the athlete. Herzschrittmacherther Elektrophysiol 2012;23:65–71. 8 Drezner J. Standardised criteria for ECG interpretation in athletes: a practical tool. Br J Sports Med 2012;46(Suppl I): i6–8. 9 Marek J, Bufalino V, Davis J, et al. Feasibility and findings of large-scale electrocardiographic screening in young adults: data from 32 561 subjects. Heart Rhythm 2011;8:1555–9. 10 Drezner JA, Ackerman MJ, Anderson J, et al. Electrocardiographic interpretation in athletes: the ‘Seattle criteria’. Br J Sports Med 2013;47. 11 Drezner JA, Fischbach P, Foelicher V, et al. Normal electrocardiographic findings: recognizing physiologic adaptations in athletes. Br J Sports Med 2013;47. 12 Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127–33. 13 Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996;276:199–204. 14 Basavarajaiah S, Wilson M, Whyte G, et al. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol 2008;51:1033–9. 15 de Noronha SV, Sharma S, Papadakis M, et al. Aetiology of sudden cardiac death in athletes in the United Kingdom: a pathological study. Heart 2009;95:1409–14. 16 Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011;58:1254–61. 17 Meyer L, Stubbs B, Fahrenbruch C, et al. Incidence, causes, and survival trends from cardiovascular-related sudden cardiac arrest in children and young adults 0 to 35 years of age: a 30-year review. Circulation 2012;126:1363–72. 18 Maron BJ. Distinguishing hypertrophic cardiomyopathy from athlete’s heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. Br J Sports Med 2009;43:649–56. 19 Ryan MP, Cleland JG, French JA, et al. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol 1995;76:689–94. 20 Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388–94. 21 Rowin EJ, Maron BJ, Appelbaum E, et al. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol 2012;110:1027–32. 22 Lakdawala NK, Thune JJ, Maron BJ, et al. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol 2011;108:1606–13. 23 Papadakis M, Carre F, Kervio G, et al. The prevalence, distribution, and clinical outcomes of electrocardiographic repolarization patterns in male athletes of African/Afro-Caribbean origin. Eur Heart J 2011;32:2304–13. 24 Papadakis M, Basavarajaiah S, Rawlins J, et al. Prevalence and significance of T-wave inversions in predominantly Caucasian adolescent athletes. Eur Heart J 2009;30:1728–35. 25 Le VV, Wheeler MT, Mandic S, et al. Addition of the electrocardiogram to the preparticipation examination of college athletes. Clin J Sport Med 2010;20: 98–105. 26 Pelliccia A, Maron BJ, Culasso F, et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000;102:278–84. 27 Di Paolo FM, Schmied C, Zerguini YA, et al. The athlete’s heart in adolescent Africans: an electrocardiographic and echocardiographic study. J Am Coll Cardiol 2012;59:1029–36. 28 Migliore F, Zorzi A, Michieli P, et al. Prevalence of cardiomyopathy in Italian asymptomatic children with electrocardiographic T-wave inversion at preparticipation screening. Circulation 2012;125:529–38. 29 Konno T, Shimizu M, Ino H, et al. Diagnostic value of abnormal Q waves for identification of preclinical carriers of hypertrophic cardiomyopathy based on a molecular genetic diagnosis. Eur Heart J 2004;25:246–51. 30 Pelliccia A, Culasso F, Di Paolo FM, et al. Prevalence of abnormal electrocardiograms in a large, unselected population undergoing pre-participation cardiovascular screening. Eur Heart J 2007;28:2006–10. 31 Sohaib SM, Payne JR, Shukla R, et al. Electrocardiographic (ECG) criteria for determining left ventricular mass in young healthy men; data from the LARGE Heart study. J Cardiovasc Magn Reson 2009;11:2. 32 Sathanandam S, Zimmerman F, Davis J, et al. Abstract 2484: ECG screening criteria for LVH does not correlate with diagnosis of hypertrophic cardiomyopathy. Circulation 2009;120:S647. 33 Weiner RB, Hutter AM, Wang F, et al. Performance of the 2010 European Society of Cardiology criteria for ECG interpretation in the athlete. Heart 2011;97:1573–7. 34 Gersh BJ, Maron BJ, Bonow RO, et al. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:e783–831. 35 Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009;54:220–8. 36 Pelliccia A, Maron MS, Maron BJ. Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete’s heart from pathologic hypertrophy. Prog Cardiovasc Dis 2012;54:387–96. 37 Rawlins J, Bhan A, Sharma S. Left ventricular hypertrophy in athletes. Eur J Echocardiogr 2009;10:350–6. 38 Maron BJ. Distinguishing hypertrophic cardiomyopathy from athlete’s heart: a clinical problem of increasing magnitude and significance. Heart 2005;91:1380–2. nummer 3 | juli 2013 | Sport & Geneeskunde 33 Pagina 32
Pagina 34Heeft u een rapport, ibrochure of internet rapporten? Gebruik Online Touch: flyer bladerbaar maken.
Sport & Geneeskunde nummer 3 | Juli 2013 Lees publicatie 24Home